Edward P. Bowman

Emergency Medicine
5501 Old York Rd Ste 1
Philadelphia, PA 19141

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates.

Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates.

Journal: Journal of medicinal chemistry
Published: April 30, 2026

Discovery of Novel N-Linked Camptothecin Linker-Payloads to Access Antibody-Drug Conjugates with High Target-Mediated In Vivo Efficacy.

Discovery of Novel N-Linked Camptothecin Linker-Payloads to Access Antibody-Drug Conjugates with High Target-Mediated In Vivo Efficacy.

Journal: Journal of medicinal chemistry
Published: April 30, 2026

Dissociation of LAG-3 inhibitory cluster from TCR microcluster by immune checkpoint blockade.

Dissociation of LAG-3 inhibitory cluster from TCR microcluster by immune checkpoint blockade.

Journal: Frontiers in immunology
Published: June 05, 2024

Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions.

Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions.

Journal: Journal for immunotherapy of cancer
Published: October 09, 2020

A capillary electrophoresis based approach for the identification of anti-drug antibodies against camelid VHH biologics (Nanobodies®).

A capillary electrophoresis based approach for the identification of anti-drug antibodies against camelid VHH biologics (Nanobodies®).

Journal: Journal of pharmacological and toxicological methods
Published: January 31, 2020

Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.

Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.

Journal: Cancer research
Published: March 21, 2016

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.

Journal: The British journal of dermatology
Published: May 22, 2015

Crosstalk among IL-23 and DNAX activating protein of 12 kDa-dependent pathways promotes osteoclastogenesis.

Crosstalk among IL-23 and DNAX activating protein of 12 kDa-dependent pathways promotes osteoclastogenesis.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: December 03, 2014

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Journal: Nature medicine
Published: December 03, 2014

Clinical improvement in psoriasis with specific targeting of interleukin-23.

Clinical improvement in psoriasis with specific targeting of interleukin-23.

Journal: Nature
Published: December 23, 2013

IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis.

IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis.

Journal: Annals of the rheumatic diseases
Published: October 21, 2013

Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.

Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.

Journal: Mucosal immunology
Published: December 21, 2012
Showing 1-12 of 15

Last Updated: 09/26/2026